



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

November 6, 2023

R. Nolan Townsend  
Chief Executive Officer  
Lexeo Therapeutics, Inc.  
345 Park Avenue South, Floor 6  
New York, NY 10010

**Re: Lexeo Therapeutics, Inc.  
Registration Statement on Form S-1  
Exhibit Nos. 10.8, 10.9, 10.10, 10.11, 10.12, 10.13, 10.14, 10.15, 10.16, 10.17, 10.18, 10.19,  
10.20, 10.21, and 10.22  
Filed November 1, 2023  
File No. 333-274777**

Dear R. Nolan Townsend:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Dayne Brown, Esq.